The only long acting somatostatin analog that is ready-to-use in a prefilled syringe
Somatuline® Depot (lanreotide) Injection
Now there's a simple, effective way to treat your patients with acromegaly: Somatuline Depot, the only somatostatin analog available in a prefilled syringe.
Somatuline® Depot (lanreotide) Injection is injected deep subcutaneously in a two-step procedure that's simple for you and for your patients.1 With a short, 20 mm needle, and an injection volume of just 0.3 mL to 0.5 mL, injections are designed to be patient- and professional-friendly.1
To make Somatuline® Depot (lanreotide) Injection accessible to as many patients as possible, it is expected to be covered by the majority of payers and widely available, including leading specialty pharmacies.2
Learn more about Somatuline® Depot (lanreotide) Injection.
Indication and Important Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.
A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).
For Full Prescribing Information, click here.
